Erythropoietin-dependent endothelial proteins: Potential use against erythropoietin resistance

Cytokine

Volumn 51, Issue 2, 2010, Pages 113-118

  Congote, Luis F ^a   Sadvakassova, Gulzhakhan ^a   Dobocan, Monica C ^a   DiFalco, Marcos R ^b   Li, Qinggang ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

CD44; Erythropoiesis; Hematopoietic stem cells; Hepcidin; Inflammation

Indexed keywords

CD131 ANTIGEN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEPCIDIN; INTERLEUKIN 3; INTERLEUKIN 3 RECEPTOR; STEM CELL FACTOR; THROMBOSPONDIN 1; ANTIINFLAMMATORY AGENT; EARLY PREGNANCY FACTOR; THROMBOSPONDIN; THROMBOSPONDIN 4;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; CD34 SELECTION; CELL CULTURE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DNA SYNTHESIS; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; ENDOTHELIUM; ENDOTHELIUM CELL; ERYTHROBLAST; ERYTHROID CELL; ERYTHROPOIESIS; EUTHYROIDISM; HEMATOPOIETIC STEM CELL; HUMAN; INFLAMMATION; IRON DEFICIENCY ANEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; UREMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHAPERONIN 10; DRUG RESISTANCE; ENDOTHELIAL CELLS; ENDOTHELIUM; ERYTHROPOIETIN; HUMANS; INTERLEUKIN-3; RECEPTORS, ERYTHROPOIETIN; THROMBOSPONDIN 1; THROMBOSPONDINS;

MUS;

EID: 77954084923     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.03.020     Document Type: Review

References (49)

1. Knudtzon S., Mortensen B.T. Growth stimulation of human bone marrow cells in agar culture by vascular cells. Blood 1975, 46:937-943.
2. Gordon M.Y., Kearney L., Hibbin J.A. Effects of human marrow stromal cells on proliferation by human granulocytic (GM-CFC), erythroid (BFU-E) and mixed (Mix-CFC) colony-forming cells. Br J Haematol 1983, 53:317-325.
3. Ascensao J.L., Vercellotti G.M., Jacob H.S., Zanjani E.D. Role of endothelial cells in human hematopoiesis: modulation of mixed colony growth in vitro. Blood 1984, 63:553-558.
4. Ohneda O., Bautch V.L. Murine endothelial cells support fetal liver erythropoiesis and myelopoiesis via distinct interactions. Br J Haematol 1997, 98:798-808.
5. Dainiak N., Warren H.B., Kreczko S., Riordan M.A., Feldman L., Lawler J., et al. Acetylated lipoproteins impair erythroid growth factor release from endothelial cells. J Clin Invest 1988, 81:834-843.
6. Kiel M.J., Morrison S.J. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 2008, 8:290-301.
7. Xie Y., Yin T., Wiegraebe W., He X.C., Miller D., Stark D., et al. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 2009, 457:97-101.
8. Li Q., Congote L.F. Bovine fetal-liver stromal cells support erythroid colony formation: enhancement by insulin-like growth factor II. Exp Hematol 1995, 23:66-73.
9. DiFalco M.R., Congote L.F. Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells. Cytokine 2002, 18:51-60.
10. Anagnostou A., Lee E.S., Kessimian N., Levinson R., Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990, 87:5978-5982.
11. Noguchi C.T., Wang L., Rogers H.M., Teng R., Jia Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 2008, 10:e36.
12. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102:1340-1346.
13. Santhanam A.V., d'Uscio L.V., Peterson T.E., Katusic Z.S. Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 2008, 29:1451-1455.
14. Westenbrink B.D., Lipsic E., van der Meer P., van der Harst P., Oeseburg H., Du Marchie Sarvaas G.J., et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007, 28:2018-2027.
15. Brines M., Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006, 70:246-250.
16. Korpelainen E.I., Gamble J.R., Smith W.B., Dottore M., Vadas M.A., Lopez A.F. Interferon-γ upregulates interleukin-3 (IL-3) receptor expression in human endothelial cells and synergizes with IL-3 in stimulating major histocompatibility complex class II expression and cytokine production. Blood 1995, 86:176-182.
17. Korpelainen E.I., Gamble J.R., Smith W.B., Goodall G.J., Qiyu S., Woodcock J.M., et al. The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor α and potentiates interleukin 8 secretion and neutrophil transmigration. Proc Natl Acad Sci USA 1993, 90:11137-11141.
18. Khew-Goodall Y., Butcher C.M., Litwin M.S., Newlands S., Korpelainen E.I., Noack L.M., et al. Chronic expression of P-selectin on endothelial cells stimulated by the T-cell cytokine, interleukin-3. Blood 1996, 87:1432-1438.
19. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2005, 305:239-242.
20. Brines M., Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008, 264:405-432.
21. Silverberg D.S., Wexler D., Blum M., Wollman Y., Schwartz D., Sheps D., et al. The interaction between heart failure, renal failure and anemia - the cardio-renal anemia syndrome. Blood Purif 2004, 22:277-284.
22. van der Putten K., Braam B., Jie K.E., Gaillard C.A. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008, 4:47-57.
23. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
24. Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010, 2010:750643.
25. Ashby D.R., Gale D.P., Busbridge M., Murphy K.G., Duncan N.D., Cairns T.D., et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009, 75:976-981.
26. Hamada Y., Fukagawa M. Is hepcidin the star player in iron metabolism in chronic kidney disease?. Kidney Int 2009, 75:873-874.
27. Gagnon R.F., Ansari M. Development and progression of uremic changes in the mouse with surgically induced renal failure. Nephron 1990, 54:70-76.
28. Gagnon R.F., Gallimore B. Characterization of a mouse model of chronic uremia. Urol Res 1988, 16:119-126.
29. Zhang F., Gagnon R.F., Richards G.K., Brox A.G. Anemia of chronic renal failure: characterization in the mouse and correction with human recombinant erythropoietin. Nephron 1996, 72:654-661.
30. Diwan A., Koesters A.G., Capella D., Geiger H., Kalfa T.A., Dorn G.W. Targeting erythroblast-specific apoptosis in experimental anemia. Apoptosis 2008, 13(8):1022-1030.
31. Congote L.F., Difalco M.R., Gibbs B.F. The C-terminal peptide of thrombospondin-4 stimulates erythroid cell proliferation. Biochem Biophys Res Commun 2004, 324:673-678.
32. Congote L.F., Sadvakassova G., Dobocan M., DiFalco M.R., Li Q. Biological activities and molecular interactions of the C-terminal residue of thrombospondin-4, an epitome of acidic amphipathic peptides. Peptides 2010, 31:723-735.
33. Dobocan M., Sadvakassova G., Congote L.F. Chaperonin 10 as an endothelial-derived differentiation factor: role of glycogen synthase kinase-3. J Cell Physiol 2009, 219:470-476.
34. Congote L.F., DiFalco M.R., Gibbs B.F. Thrombospondin 1, produced by endothelial cells under the action of erythropoietin, stimulates thymidine incorporation into erythroid cells and counteracts the inhibitory action of insulin-like growth factor binding protein 3. Cytokine 2005, 30:248-253.
35. Stier S., Ko Y., Forkert R., Lutz C., Neuhaus T., Grunewald E., et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 2005, 201:1781-1791.
36. Sadvakassova G., Dobocan M., Congote L.F. Osteopontin and the C-terminal peptide of thrombospondin-4 compete for CD44 binding and have opposite effects on CD133+ cell colony formation. BMC Res Notes 2009, 2:215.
37. Wang K.X., Denhardt D.T. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008, 19:333-345.
38. Sadvakassova G., Dobocan M., DiFalco M.R., Congote L.F. Regulator of differentiation 1 (ROD1) binds to the amphipathic C-terminal peptide of thrombospondin-4 and is involved in its mitogenic activity. J Cell Physiol 2009, 220:672-679.
39. Doyen V., Rubio M., Braun D., Nakajima T., Abe J., Saito H., et al. Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J Exp Med 2003, 198:1277-1283.
40. Kang J.A., Zhou Y., Weis T.L., Liu H., Ulaszek J., Satgurunathan N., et al. Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts. J Biol Chem 2008, 283:6997-7006.
41. Vanags D., Williams B., Johnson B., Hall S., Nash P., Taylor A., et al. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 2006, 368:855-863.
42. Johnson B.J., Le T.T., Dobbin C.A., Banovic T., Howard C.B., Flores F.M., et al. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem 2005, 280:4037-4047.
43. Kielczewski J.L., Jarajapu Y.P., McFarland E.L., Cai J., Afzal A., Li Calzi S., et al. Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res 2009, 105:897-905.
44. Granata R., Trovato L., Garbarino G., Taliano M., Ponti R., Sala G., et al. Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J 2004, 18:1456-1458.
45. Muck C., Micutkova L., Zwerschke W., Jansen-Durr P. Role of insulin-like growth factor binding protein-3 in human umbilical vein endothelial cell senescence. Rejuvenation Res 2008, 11:449-453.
46. Tam B.Y., Wei K., Rudge J.S., Hoffman J., Holash J., Park S.K., et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006, 12:793-800.
47. Wojakowski W., Kazmierski M., Korzeniowska B., Tendera M. Link between erythropoietin release and mobilization of endothelial progenitor cells in acute myocardial infarction. Eur Heart J 2007, 28:1785-1786.
48. Satoh K., Kagaya Y., Nakano M., Ito Y., Ohta J., Tada H., et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006, 113:1442-1450.
49. Sigounas G., Steiner M., Anagnostou A. Synergism of hemopoietic growth factors on endothelial cell proliferation. Angiology 1997, 48:141-147.